FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

por O’Farrell, Marie, Duke, Greg, Crowley, Richard, Buckley, Douglas, Martins, Eduardo B., Bhattacharya, Dipankar, Friedman, Scott L., Kemble, George
Publicado 2022

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

por Falchook, Gerald, Infante, Jeffrey, Arkenau, Hendrik-Tobias, Patel, Manish R., Dean, Emma, Borazanci, Erkut, Brenner, Andrew, Cook, Natalie, Lopez, Juanita, Pant, Shubham, Frankel, Arthur, Schmid, Peter, Moore, Kathleen, McCulloch, William, Grimmer, Katharine, O'Farrell, Marie, Kemble, George, Burris, Howard
Publicado 2021

Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy

por Talebi, Ali, de Laat, Vincent, Spotbeen, Xander, Dehairs, Jonas, Rambow, Florian, Rogiers, Aljosja, Vanderhoydonc, Frank, Rizotto, Lara, Planque, Mélanie, Doglioni, Ginevra, Motamedi, Sahar, Nittner, David, Roskams, Tania, Agostinis, Patrizia, Bechter, Oliver, Boecxstaens, Veerle, Garmyn, Marjan, O’Farrell, Marie, Wagman, Alan, Kemble, George, Leucci, Eleonora, Fendt, Sarah-Maria, Marine, Jean-Christophe, Swinnen, Johannes V.
Publicado 2023